Show simple item record

dc.contributor.authorMoore, Nathan F.en_US
dc.contributor.authorAzarova, Anna M.en_US
dc.contributor.authorBhatnagar, Namrataen_US
dc.contributor.authorRoss, Kenneth N.en_US
dc.contributor.authorDrake, Lauren E.en_US
dc.contributor.authorFrumm, Staceyen_US
dc.contributor.authorLiu, Qinsong S.en_US
dc.contributor.authorChristie, Amanda L.en_US
dc.contributor.authorSanda, Takaomien_US
dc.contributor.authorChesler, Louisen_US
dc.contributor.authorKung, Andrew L.en_US
dc.contributor.authorGray, Nathanael S.en_US
dc.contributor.authorStegmaier, Kimberlyen_US
dc.contributor.authorGeorge, Rani E.en_US
dc.date.accessioned2014-12-02T21:27:04Z
dc.date.issued2014en_US
dc.identifier.citationMoore, N. F., A. M. Azarova, N. Bhatnagar, K. N. Ross, L. E. Drake, S. Frumm, Q. S. Liu, et al. 2014. “Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.” Oncotarget 5 (18): 8737-8749.en
dc.identifier.issn1949-2553en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:13454624
dc.description.abstractMutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALKF1174L mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in ALK-translocated cancers. We have shown that the combination of crizotinib and an inhibitor of downstream signaling induces a favorable response in transgenic mice bearing ALKF1174L/MYCN-positive neuroblastoma. Here, we investigated the molecular basis of this effect and assessed whether a similar strategy would be effective in ALK-mutated tumors lacking MYCN overexpression. We show that in ALK-mutated, MYCN-amplified neuroblastoma cells, crizotinib alone does not affect mTORC1 activity as indicated by persistent RPS6 phosphorylation. Combined treatment with crizotinib and an ATP-competitive mTOR inhibitor abrogated RPS6 phosphorylation, leading to reduced tumor growth and prolonged survival in ALKF1174L/MYCN-positive models compared to single agent treatment. By contrast, this combination, while inducing mTORC1 downregulation, caused reciprocal upregulation of PI3K activity in ALK-mutated cells expressing wild-type MYCN. Here, an inhibitor with potency against both mTOR and PI3K was more effective in promoting cytotoxicity when combined with crizotinib. Our findings should enable a more precise selection of molecularly targeted agents for patients with ALK-mutated tumors.en
dc.language.isoen_USen
dc.publisherImpact Journals LLCen
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226718/pdf/en
dash.licenseLAAen_US
dc.subjectALKen
dc.subjectneuroblastomaen
dc.subjectcrizotiniben
dc.subjectmTOR inhibitoren
dc.subjectMYCNen
dc.titleMolecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastomaen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOncotargeten
dash.depositing.authorRoss, Kenneth N.en_US
dc.date.available2014-12-02T21:27:04Z
dash.authorsorderedfalse
dash.contributor.affiliatedRoss, Kenneth
dash.contributor.affiliatedGray, Nathanael


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record